Ion Exchange India Ltd-$ — Q1 FY27 earnings call
Summary generated by AI from the official transcript Ion Exchange India Ltd-$ filed with BSE on 17 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Ion Exchange reported consolidated Q1 FY27 operating income of INR 701 crores, up 20% year-on-year, while EBITDA declined 49% to INR 32 crores and net profit was INR 3 crores. Management introduced a reclassification of reporting segments, splitting the former engineering segment into Treatment Solutions, Industrial Products and Lifecycle Services, alongside existing Specialty Chemicals and Consumer Products segments. Management attributed the profitability decline to legacy project losses in Treatment Solutions, higher input and Roha-related costs in Specialty Chemicals, and geopolitical factors affecting invoicing and raw material costs.
Numbers mentioned
Operating income: INR 701 crores (Q1 FY27)
p. 22
“the company reported an operating income of INR 701 crores, increase of 20% year-on-year”
Vasant Naik, page 22 of the filed PDF · View the filing
EBITDA: INR 32 crores (Q1 FY27)
p. 22
“The EBITDA stood at INR 32 crores, which declined by 49% year-on-year.”
Vasant Naik, page 22 of the filed PDF · View the filing
EBITDA margin: 4.54% (Q1 FY27)
p. 22
“The EBITDA margin stood at 4.54%, and net profit was INR 3 crores, while the PAT margin was 0.44%.”
Vasant Naik, page 22 of the filed PDF · View the filing
Treatment Solutions revenue: INR 210 crores (Q1 FY27)
p. 23
“The treatment solutions segment reported a revenue of INR 210 crores, an increase of 14% year-on-year.”
Vasant Naik, page 23 of the filed PDF · View the filing
Treatment Solutions EBIT: loss of INR 17 crores (Q1 FY27)
p. 23
“The Segment reported an EBIT level loss of INR 17 crores, with profitability continues to be impacted by certain legacy projects.”
Vasant Naik, page 23 of the filed PDF · View the filing
Industrial Products revenue: INR 105 crores (Q1 FY27)
p. 23
“revenue growing 14% year-on-year to INR 105 crores”
Vasant Naik, page 23 of the filed PDF · View the filing
Industrial Products EBIT margin: 11.89% (Q1 FY27)
p. 23
“EBIT margin improved significantly to 11.89% from less than 6% in the corresponding quarter of last year”
Vasant Naik, page 23 of the filed PDF · View the filing
Lifecycle Services revenue: INR 72 crores (Q1 FY27)
p. 23
“The Lifecycle Services maintained its healthy growth trajectory, with revenue increasing 28% year-on-year to INR 72 crores.”
Vasant Naik, page 23 of the filed PDF · View the filing
Lifecycle Services EBIT margin: 9.92% (Q1 FY27)
p. 23
“EBIT margin was 9.92% as compared with 10.55% in the previous year, Primarily reflecting higher input cost.”
Vasant Naik, page 23 of the filed PDF · View the filing
Order book: INR 2,473 crores (as of June 2026)
p. 23
“Across these three businesses, our order book stood at INR 2,473 crores as of June 2026, providing healthy execution visibility.”
Vasant Naik, page 23 of the filed PDF · View the filing
Bid pipeline: INR 9,777 crores
p. 23
“the bid pipeline stood at INR 9,777 crores, providing a strong opportunity funnel for future order inflows.”
Vasant Naik, page 23 of the filed PDF · View the filing
Specialty Chemicals revenue: INR 230 crores (Q1 FY27)
p. 23
“revenue for the quarter stood at INR 230 crores, an increase of 21% year-on-year.”
Vasant Naik, page 23 of the filed PDF · View the filing
Specialty Chemicals EBIT: INR 22 crores (Q1 FY27)
p. 23
“The segment EBIT stood at INR 22 crores, reflecting a decline of 52% year-on-year.”
Vasant Naik, page 23 of the filed PDF · View the filing
Consumer Products revenue: INR 112 crores (Q1 FY27)
p. 24
“revenue increasing 33% year-on-year to INR 112 crores”
Vasant Naik, page 24 of the filed PDF · View the filing
Consumer Products segment loss: INR 34 lakhs (Q1 FY27)
p. 24
“The segment reported a loss of approximately INR 34 lakhs, compared with a loss of INR 45 lakhs in the corresponding quarter last year”
Vasant Naik, page 24 of the filed PDF · View the filing
Specialty chemicals FY26 revenue: just under INR 900 crore (FY26)
p. 25
“currently, our specialty chemical, as you just mentioned, is just under INR 900 crore for the year for ’25-’26.”
Vasant Naik, page 25 of the filed PDF · View the filing
Roha impact on chemical segment margin: approximately 6% (Q1 FY27)
p. 31
“The impact of Roha on the chemical segment margin was approximately 6% at the segment level.”
Vasant Naik, page 31 of the filed PDF · View the filing
UP project unexecuted portion: around 11% of order backlog (as of June 2026)
p. 34
“The UP unexecuted portion is around 11% of the order backlog as of June.”
Vasant Naik, page 34 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Roha/Ankleshwar resin capacity expansion — 5x the original capacity of Ankleshwar
stated firmly by Indraneel Dutt
p. 13
“After these works, total resin capacity across the two sites is expected to reach approximately 5x the capacity that existed before construction of the Roha plant.”
Indraneel Dutt, page 13 of the filed PDF · View the filing
Global resin market share — 10% of the global resin volume
stated as an aspiration by Indraneel Dutt
p. 13
“we are aspiring to take 10% of the global resin volume, which I think is a fairly big aspiration from that perspective.”
Indraneel Dutt, page 13 of the filed PDF · View the filing
Pharma resin capacity expansion — 6x capacity · next 12 months
stated conditionally by Indraneel Dutt
p. 19
“We believe that we are on course to get that done in the next 12 months.”
Indraneel Dutt, page 19 of the filed PDF · View the filing
Specialty chemicals asset turnover post Roha full capacity — just under 2x asset turnover on manufacturing capex; at least 50% increase in capacity · next four years
stated conditionally by Vasant Naik
p. 25
“We had said in the past that we expect once the Roha plant achieves full capacity over the next four years, we should have an asset turnover of just under 2x on the manufacturing CapEx, which we are incurring.”
Vasant Naik, page 25 of the filed PDF · View the filing
Roha plant utilization — 25% utilization for the first year · first year of operation
stated conditionally by Indraneel Dutt
p. 30
“we continue to hold on, ma'am. This is about four months of the year gone. It has been softer than what we expected. But at this point in time, we are not throwing in the towel.”
Indraneel Dutt, page 30 of the filed PDF · View the filing
Consumer products profitability — break even · this financial year
stated as an aspiration by Indraneel Dutt
p. 30
“So our plan is to see if we can break even in this financial year. That is the first target for us.”
Indraneel Dutt, page 30 of the filed PDF · View the filing
UP legacy project closure — spill over to next financial year · next financial year
stated conditionally by Indraneel Dutt
p. 29
“As of now, the way the funds flow are happening, it will spill over to the next financial year because there is a huge amount of work that is still left to be done.”
Indraneel Dutt, page 29 of the filed PDF · View the filing
Legacy project completion (non-UP large project) — significant part of the work completed · this financial year
stated conditionally by Indraneel Dutt
p. 29
“we are saying a significant part of that big legacy project should make progress by the end of this financial year.”
Indraneel Dutt, page 29 of the filed PDF · View the filing
Company-wide profitability — restore double-digit profitability · over time
stated as an aspiration by Indraneel Dutt
p. 26
“We are working across these areas to restore double-digit profitability over time.”
Indraneel Dutt, page 26 of the filed PDF · View the filing
Roha volume allocation to North America — significant part of Roha capacity utilization from overseas, specifically North America
stated conditionally by Indraneel Dutt
p. 19
“we expect a significant part of our Roha plant capacity utilization to come from overseas markets and specifically the North American market.”
Indraneel Dutt, page 19 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management clarified the 5x figure is a global capacity number covering both Roha and Ankleshwar, achieved in phases, and not a direct multiplier of last year's chemical segment revenue.
Answered by Indraneel Dutt
Asked by Pratik Kothari: What does the 5x capacity expansion figure for Roha actually refer to, and what was the resin revenue base last year?
p. 13
“We are increasing resin capacity by expanding Roha and de‑bottlenecking both Roha and Ankleshwar.”
Indraneel Dutt, page 13 of the filed PDF · View the filing
Management said the segment has faced headwinds from large legacy projects and that it is being more selective in project selection and moving toward higher-value advanced and emerging solutions.
Answered by Indraneel Dutt
Asked by Kaustav Bubna: Why has Treatment Solutions EBIT fallen from INR 60 crore to INR 27 crore despite revenue growth, and how will profitability be restored?
p. 16
“we continue to look at ways of how we can improve the solutions business profitability. A, in terms of being selective and picking up projects which are definitely much better risk profile”
Indraneel Dutt, page 16 of the filed PDF · View the filing
Management said the company is being selective on projects and moving toward high-tech advanced/emerging solutions to improve the mix, but noted the business is not yet out of the woods.
Answered by Indraneel Dutt
Asked by Sagar Parekh: Given past 10-11% EBIT margins on lower revenue in FY21-22, can Treatment Solutions return to those margins at scale?
p. 22
“we don't want to give a feeling that we are out of the woods. We are not.”
Indraneel Dutt, page 22 of the filed PDF · View the filing
Management acknowledged Q1 performance was disappointing due to legacy projects, Roha ramp-up, and geopolitical impacts, but expects the outlook to improve as these factors resolve.
Answered by Indraneel Dutt
Asked by Kaustav Bubna: How does the company view the year ahead for profitability recovery across segments?
p. 25
“I agree that the performance in the first quarter has been disappointing, and it is a combination, as you said, some of the legacy projects which continue to grind through.”
Indraneel Dutt, page 25 of the filed PDF · View the filing
Management corrected that they never guided full resolution this financial year, and said closure now depends on government fund flow and will likely spill into next financial year.
Answered by Indraneel Dutt
Asked by Norris Crasto: Is the UP legacy project still on track to be resolved by the end of the calendar/financial year as previously indicated?
p. 28
“We have never said that the UP contract will be fully over in this financial year.”
Indraneel Dutt, page 28 of the filed PDF · View the filing
Management said utilization has been softer than expected but they are still targeting the guidance and will update after Q2.
Answered by Indraneel Dutt
Asked by Richa Chowdhary: Is the previously guided 25% Roha utilization for the first year still achievable given the geopolitical situation?
p. 30
“It has been softer than what we expected. But at this point in time, we are not throwing in the towel.”
Indraneel Dutt, page 30 of the filed PDF · View the filing
Management quantified the Roha impact at about 6% of segment margin, with additional 3-4% from the absence of a prior-year forex gain, and cost pass-through lag.
Answered by Vasant Naik
Asked by Pratik Kothari: Excluding Roha-related costs, what would chemical segment margins look like this quarter versus last year?
p. 31
“So, in the current quarter, there is no foreign exchange gain. So that impact is almost around 3% to 4%.”
Vasant Naik, page 31 of the filed PDF · View the filing
Management said a significant part of the project is complete but a sizable portion remains, and the plan is to offset the impact with more profitable new projects like Hyundai.
Answered by Indraneel Dutt
Asked by Saket Kapoor: Is the worst of the P&L impact from legacy Treatment Solutions projects behind the company?
p. 34
“a significant part of the project is behind us, though a sizable portion still remains — that's the extent of the quantification I can offer at this stage.”
Indraneel Dutt, page 34 of the filed PDF · View the filing
Risks flagged
Legacy project losses continuing to impact Treatment Solutions profitability
p. 23
“The Segment reported an EBIT level loss of INR 17 crores, with profitability continues to be impacted by certain legacy projects.”
Vasant Naik, page 23 of the filed PDF · View the filing
Geopolitical situation affecting invoicing and input costs
p. 25
“It is also a combination of the current geopolitical situation due to which some of our invoicing got impacted.”
Indraneel Dutt, page 25 of the filed PDF · View the filing
UP project execution dependent on constrained government fund flow
p. 29
“it is entirely dependent on the fund flow that is coming into these projects, which we are all aware that has been severely constrained and restricted in the whole of the last financial year.”
Indraneel Dutt, page 29 of the filed PDF · View the filing
Potential deferral of Hyundai contract due to Strait of Hormuz / geopolitical exposure
p. 30
“We don't anticipate any delay as of now. However, if the crisis geopolitically continues, then there will be cause for worry.”
Indraneel Dutt, page 30 of the filed PDF · View the filing
Cost overruns on large legacy project impacting Treatment Solutions headwind
p. 32
“part of the headwind on treatment solutions does stem from cost overruns on this specific project — it's a large project within the portfolio, so it does have a meaningful impact.”
Indraneel Dutt, page 32 of the filed PDF · View the filing
Softening in industrial products growth due to West Asia crisis
p. 10
“There were some impacts because of West Asia crisis. We could not keep up on the same rate of growth.”
Indraneel Dutt, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.